When we look at how those uh results apply to individual patients, we see some stratification based on subtypes. So anaplastic large cell lymphoma, uh, these are universally CD30 expressing T cell lymphomas. Um, the two main systemic subtypes are a positive ALCL. They expect express the a protein and AC negative ALCL. And when you look at chemotherapy or intensified chemotherapy approaches, the patients with AC. ALCL do the best or have the highest cure rates with combination chemotherapy. Patients without negative ALCL do the next best, and then we usually see patients with what used to be called AITL, angio immunoblastic T-cell lymphoma, and now we refer to that often as a group of diseases which we call follicular helper T cell lymphomas, um, and then peripheral T-cell lymphoma, not otherwise specified, you know, so that's kind of the order in terms of prognosis. The main advances we've had so far in terms of progression-free and overall survival has been with the anaplastic large cell lymphoma patients, where when we add renttuximab, thedotin, CD30 targeting antibody drug conjugate, we increased the CR rate, the progression-free survival rate, and the overall survival rate for those patients. So pretty much that's a universal standard is renttuximab in combination with chemotherapy, the Pivotal study used CHP, cyclophosphamide, doxorubicin, prednisone dropped the vincristine due to over concerns of overlapping toxicity, but there's been subsequent data with other intensified regimens, uh, uh, adding it to COP plusotopicide or EPOC or following that with transplant. But adding renttuximab to combination chemotherapy seems to really push up the cure rates for those patients. In that study, a subsets of patients with angioimmunoblastic or um. Follicular helper or peripheral T cell lymphoma NOS with CD30 expression were included. The results are less clear for those patients. There does appear to be potentially some benefit in the higher CD30 expressing PTCL, uh, but those were smaller subsets and really the driver of overall survival benefit was anaplastic large cell lymphoma.
Presenter
